MRI parameters for the whole patient group, as well as separately for patients who showed clinical disease progression and those who did not
| Whole group (n=54) | No progression (n=25) | Progression (n=29) | p Value | |
| aPBVC 0–2 | −0.44 (−0.62; −0.04) | −0.27 (−0.61; −0.00) | −0.51 (−0.70; −0.21) | 0.09 |
| aPBVC 2–5.5 | −0.32 (−0.47; −0.12) | −0.25 (−0.45; −0.12) | −0.36 (−0.49; −0.14) | 0.49 |
| aPVVC 0–2 | 4.28 (1.64; 7.01) | 3.23 (−0.1; 6.02) | 4.76 (3.05; 9.17) | 0.02 |
| aPVVC 2–5.5 | 1.89 (0.62; 3.72) | 1.73 (0.30; 4.08) | 2.23 (1.16; 3.81) | 0.34 |
| T1LL bl (cm3) | 0.25 (0; 0.58) | 0.12 (0; 0.53) | 0.25 (0.085; 0.70) | 0.21 |
| T1LL fu (cm3) | 0.18 (0.02; 0.69) | 0.05 (0; 0.35) | 0.21 (0.116; 0.98) | 0.0504 |
| T2LL bl (cm3) | 3.07 (1.17; 7.24) | 2.4 (1.0; 7.4) | 3.7 (1.2; 7.4) | 0.61 |
| T2LL fu (cm3) | 4.00 (1.41; 8.94) | 2.77 (1.12; 8.37) | 4.4 (1.67; 10.6) | 0.43 |
| GdLL bl (cm3) | 0 (0; 0.2) | 0 (0; 0.2) | 0 (0; 0.2) | 0.44 |
| ΔT1LL 0–2 years | 0 (−0.04; 0.14) | 0 (−0.08; 0.10) | 0.02 (−0.04; 0.19) | 0.36 |
| ΔT2LL 0–2 years | 0.45 (−0.12; 1.64) | 0.6 (−0.07; 1.53) | 0.37 (−0.38; 2.56) | 0.87 |
Data are presented as median (IQR). Progression is increase in EDSS of at least 1 point over the entire 5.5 year follow-up period; p value is p value for comparison between progressing and non-progressing patients performed using the Mann–Whitney U test; IQR 25%–75%.
0–2, time interval between baseline and 2 years of follow-up; 2–5.5, time interval between 2 and 5.5 years of follow-up; Δ, difference between two time points; aPBVC, annual percentage brain volume change; aPVVC, annual percentage ventricular volume change; bl, baseline; EDSS, Expanded Disability Status Scale; fu, follow-up (after 2 years); GdLL, lesion load of enhancing lesions; T1LL, T1 lesion load; T2LL, T2 lesion load.